Company intelligence / Profile preview

FRILAB

Geneva, Geneva, Switzerland

Ownership: Private
Development stage: Other

Overview

FRILAB Laboratories commercializes a broad range of pharmaceutical products for various health indications, focusing on emerging markets, and supplies both in-house and in-licensed molecules that meet European quality standards. There is no public disclosure of recent clinical trial results; the company appears to specialize in supply, registration, and distribution, rather than novel drug discovery and clinical stage R&D[1][2][3][7].

Therapeutic areas: Women's HealthMetabolic DisordersOther
Modalities: Small moleculeBiologicProteinRecombinant protein
Industry: Biotech

Drug pipeline

8 assets

Ascabiol

Unknown

7 more assets in the full pipeline.

Request access →

Partnerships

Local certified exporters and manufacturers in Africa, Middle East, Eurasia, Maghreb, South America, and Southeast Asia[1][2].

Beyond the preview

Go deeper on FRILAB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FRILAB.

Explore the full profile